Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2007 Results
Date:11/8/2007

Submits Iloperidone New Drug Application (NDA); Begins Phase III Chronic Insomnia Study for VEC-162; Reports Results in VSF-173 Phase II Proof of

Concept Trial; Updates Full Year 2007 Financial Guidance

ROCKVILLE, Md., Nov. 8 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced financial and operational results for the third quarter ended September 30, 2007.

Vanda reported research and development (R&D) expenses in the third quarter of 2007 of $13.9 million, compared to second quarter of 2007 R&D expenses of $10.2 million and third quarter of 2006 R&D expenses of $9.5 million. The increase in R&D expenses in the third quarter of 2007 relative to the second quarter of 2007 is primarily attributable to a $5.0 million milestone charge resulting from the submission of the iloperidone NDA, which was partially offset by lower clinical trial costs associated with the completion of the long-term open label portion of the Phase III trial for iloperidone. The increase in R&D expenses in the third quarter of 2007 relative to the third quarter of 2006 was also primarily attributable to the $5.0 million NDA milestone charge, which was partially offset by lower clinical trial expenses for the company's iloperidone and VEC-162 Phase III trials that were primarily completed in 2006. Total expenses for the third quarter of 2007 were $23.5 million, compared to $17.6 million in the second quarter of 2007 and $12.8 million in the third quarter of 2006.

Net loss applicable to common stockholders was $21.9 million for the third 660,697 (143,303)

Accrued expenses 5,544,227 5,329,690

Deferred grant revenue (140,599) -

Other liabilities 13,258 209,851

Net cash used in operating

activities (35,019,750) (40,503,262)

Cash flows from investing activities:

Purchases of property and equipment (249,728) (1,187,295)

Proceeds from sales of property and

equipment 119,054 -

Purchases of marketable securities (107,570,370) (101,313,078)

Proceeds from sales of marketable

securities - 82,137,888

Maturities of marketable securities 60,395,000 18,520,000

Net cash used in investing

activities (47,306,044) (1,842,485)

Cash flows from financing activities:

Principal payments on obligations

under capital lease - (1,071)

Principal payments on note payable - (141,074)

Proceeds from exercise of stock

options and warrants 103,176 48,886

Proceeds from issuance of common

stock, net of issuance costs 111,254,850 53,329,951

Net cash provided by financing

activities 111,358,026 53,236,692

Effect of foreign currency translation (6,654) (3,781)

Net increase in cash and cash

equivalents 29,025,578 10,887,164

Cash and cash equivalents, beginning

of period 30,928,895 21,012,815

Cash and cash equivalents, end of

period $59,954,473 $31,899,979

quarter of 2007, compared to $16.0 million in the second quarter of 2007 and $12.1 million in the third quarter of 2006. Net loss per share applicable to common stockholders for the third quarter of 2007 was $0.82, compared to $0.60 in the second quarter of 2007, and $0.55 in the third quarter of 2006.

As of September 30, 2007, Vanda's cash, cash equivalents, and marketable securities totaled $109.4 million. As of September 30, 2007, the company had a total of approximately 26.6 million shares of common stock outstanding.

OPERATIONAL HIGHLIGHTS

Iloperidone

On September 27, 2007 Vanda announced that it had submitted an NDA to the U.S. Food and Drug Administration (FDA) for iloperidone, its investigational atypical antipsychotic for the treatment of schizophrenia.

VEC-162

Vanda announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of VEC-162 in chronic primary insomnia. The trial is a randomized, double-blind, placebo-controlled study, and will enroll approximately 400 patients. The trial will measure time to fall asleep and sleep maintenance, as well as next-day performance and mood. Vanda expects results in the fourth quarter of 2008.

VSF-173

On October 30, 2007 Vanda announced top-line results from a Phase II clinical trial evaluating VSF-173 in excessive sleepiness.

FINANCIAL DETAILS

-- Operating Expenses. Third quarter 2007 R&D expenses, primarily

consisting of salaries and related costs of R&D personnel, stock-based

compensation, licensing fees, and the costs of consultants, materials

and supplies associated with the company's clinical trials and research

initiatives, were $13.9 million, up from $10.2 million in the previous

quarter and up from $9.5 million in the third quarter of 2006. The

increase in R&D expenses in the third quarter of 2007 relative to the

second quarter of 2007 was primarily attributable to a $5.0 million

milestone charge resulting from the submission of the iloperidone NDA,

which was partially offset by lower clinical trial costs related to the

completion of the long-term open label portion of the Phase III trial

for iloperidone. The increase in R&D expenses in the third quarter of

2007 relative to the third quarter of 2006 was also primarily

attributable to the $5.0 million NDA milestone charge, which was

partially offset by lower clinical trial expenses for the company's

iloperidone and VEC-162 Phase III trials that were primarily completed

in 2006.

General and administrative (G&A) expenses totaled $9.6 million in the

third quarter of 2007, up from $7.4 million in the second quarter of

2007, and up from $3.3 million in the third quarter of 2006. The

increase in G&A expenses in the third quarter of 2007 relative to the

second quarter of 2007 was primarily attributable to an increase in

marketing costs associated with the pre-launch commercial activities

for iloperidone. The increase in G&A expenses in the third quarter of

2007 relative to the third quarter of 2006 was primarily due to

increased marketing costs associated with the pre-launch commercial

activities, stock-based compensation charges, salaries and related

costs of non-R&D personnel, insurance and facility expenses.

Employee stock-based compensation expense recorded in the third quarter

of 2007 was $5.2 million, or $0.19 per share. Of the total $5.2

million, $1.1 million was recorded in R&D expenses and $4.1 million was

recorded in G&A expenses. In the second quarter of 2007 and the third

quarter of 2006, total stock-based compensation was $5.1 million and

$1.5 million, respectively.

-- Net loss applicable to common stockholders for the third quarter of

2007 was $21.9 million. This compares to a net loss of $16.0 million

in the second quarter of 2007, and $12.1 million in the third quarter

of 2006.

-- Net loss per share applicable to common stockholders for the third

quarter of 2007 was $0.82, compared to $0.60 in the second quarter of

2007 and $0.55 in the third quarter of 2006.

-- Cash and marketable securities decreased by $10.3 million during the

third quarter. Changes included $21.9 million of operating losses,

offset by increases in accrued R&D expenses and accounts payable of

$6.4 million, $5.3 million of non-cash depreciation, amortization, and

stock-based compensation expenses, and net decreases in other working

capital of $0.1 million.

-- The balance sheet at the end of the third quarter of 2007 reflected

$109.4 million of unrestricted cash, cash equivalents and marketable

securities, compared to $119.7 million as of June 30, 2007, and $31.9

million as of December 31, 2006.

FINANCIAL GUIDANCE

Vanda is updating its full year 2007 financial guidance as a result of favorable variances from expected spending levels, and a later-than-planned initiation of the VEC-162 trial in primary insomnia. Full year financial results are now expected to show total cash used in company operations to be approximately $55 million to $60 million, or $25 million to $30 million less than previously reported. The total cash balance at December 31, 2007 is now expected to be in the range of $85 million to $90 million. Vanda anticipates that its current funds will be sufficient to continue its pre-launch commercial activities for iloperidone, the ongoing VEC-162 Phase III trial for chronic sleep disorders and additional R&D activities into mid-2008.

Net loss for the year is expected to be between $70 million to $75 million, or approximately $2.66 to $2.84 per share. Non-cash charges for 2007, consisting primarily of stock-based compensation expense and depreciation and amortization, are expected to be approximately $20 million. Per share figures were computed on a weighted average basis of 26,362,723 shares of common stock outstanding at the end of the year.

CONFERENCE CALL

The company has scheduled a conference call for today, Thursday, November 8, 2007 at 10:30 AM ET. During the call, Mihael H. Polymeropoulos, M.D., President and CEO, and Steven A. Shallcross, Sr. Vice President and CFO, will discuss quarterly results and other corporate activities. Investors can call 1-866-578-5801 (domestic) and 1-617-213-8058 (international) prior to the 10:30 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos. A replay of the call will be available Thursday, November 8, 2007, at 12:30 PM ET and will be accessible until Thursday, November 15, 2007, at 5:00 PM ET. The replay call-in number is 1- 888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 60186931.

The conference call will be broadcast simultaneously on the company's Web site, http://www.vandapharma.com. Investors should click on the Investor Relations tab and are advised to go to the Web site at least 15 minutes early to register, download, and install any necessary software. The call will also be archived on the Vanda Web site for a period of 30 days, through December 8, 2007.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder, for which Vanda has recently submitted an NDA to the FDA. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders, which is currently in Phase III for sleep disorders. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness, which recently completed its Phase II study. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

NOTE REGARDING FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Vanda's plans for its product candidates. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, a failure of Vanda's product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for the company's products or to comply with ongoing regulatory requirements, a lack of acceptance of Vanda's product candidates in the marketplace, a failure of the company to become or remain profitable, Vanda's inability to obtain the capital necessary to fund its research and development activities, a loss of any of the company's key scientists or management personnel, and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's report on Form 10-Q for the quarter ended June 30, 2007 (File No. 000-51863). No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

VANDA PHARMACEUTICALS INC.

(A Development Stage Enterprise)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

Three Months Ended Nine Months Ended

Sept. 30, Sept. 30, Sept. 30, Sept. 30,

2007 2006 2007 2006

Revenues from

services $- $- $- $-

Operating expenses:

Research and

development 13,874,248 9,542,385 34,660,132 44,130,788

General and

administrative 9,647,646 3,264,849 23,330,570 9,170,439

Total

operating

expenses 23,521,894 12,807,234 57,990,702 53,301,227

Loss from

operations (23,521,894) (12,807,234) (57,990,702) (53,301,227)

Interest income 1,514,708 683,469 4,608,143 1,686,363

Interest expense - (396) - (4,829)

Other income 71,345 - 71,345 -

Total other

income,

net 1,586,053 683,073 4,679,488 1,681,534

Loss before tax

provision (21,935,841) (12,124,161) (53,311,214) (51,619,693)

Income tax

provision 7,660 - 10,070 -

Net loss $(21,943,501) $(12,124,161) $(53,321,284) $(51,619,693)

Basic and diluted

net loss per

common share $(0.82) $(0.55) $(2.03) $(3.72)

Shares used in

calculation of

basic and diluted

net loss per

common share 26,612,853 21,871,542 26,223,151 13,862,613

VANDA PHARMACEUTICALS INC.

(A Development Stage Enterprise)

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

September 30, 2007 December 31, 2006

ASSETS

Current assets:

Cash and cash equivalents $59,954,473 $30,928,895

Marketable securities 45,474,370 941,981

Prepaid expenses, deposits and

other current assets 3,439,284 1,949,466

Total current assets 108,868,127 33,820,342

Marketable securities, long-term 3,992,347 -

Property and equipment, net 1,444,925 1,859,704

Deposits 150,000 150,000

Restricted cash 430,230 430,230

Total assets $114,885,629 $36,260,276

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable $3,446,423 $2,783,249

Accrued expenses 11,868,130 6,322,808

Total current liabilities 15,314,553 9,106,057

Long-term liabilities:

Deferred rent 280,655 238,413

Deferred grant revenue - 129,950

Other long-term liabilities - 28,984

Total liabilities 15,595,208 9,503,404

Stockholders' equity:

Common stock 26,643 22,129

Additional paid-in capital 252,412,208 126,578,588

Accumulated other comprehensive

gain (loss) 13,430 (3,269)

Deficit accumulated during the

development stage (153,161,860) (99,840,576)

Total stockholders' equity 99,290,421 26,756,872

Total liabilities and

stockholders' equity $114,885,629 $36,260,276

VANDA PHARMACEUTICALS INC.

(A Development Stage Enterprise)

CONDENSED CONSOLIDATED STATEMENTS OF

CASH FLOWS (Unaudited)

Nine Months Ended

September 30, September 30,

2007 2006

Cash flows from operating activities:

Net loss $(53,321,284) $(51,619,693)

Adjustments to reconcile net income

to net cash used in operating

activities:

Depreciation and amortization 446,806 415,197

Employee and non-employee stock-

based compensation 14,480,108 4,525,202

Loss on disposal of assets 27,017 29,528

Accretion of discount on investments (1,315,609) (301,293)

Changes in assets and liabilities:

Prepaid expenses and other current

assets (1,414,371) 391,559

Deposits - 660,000

Accounts payable
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... videos a whole new perspective by using the title layers in ProSlice Levels ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
Breaking Medicine News(10 mins):